Cellectis bioresearch and Lonza Enter Development and Commercial Manufacturing Agreement
Advertisement
Cellectis bioresearch, subsidiary of Cellectis, and Lonza announced that the companies have entered into an agreement for the development and commercialization of a bioengineered cell line.
Cellectis bioresearch will use its meganucleases to deactivate (knock-out) the glutamine synthetase (GS) in CHOK1SV, Lonza’s proprietary host cell line. Meganucleases are molecular scissors that can be directed to a single highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene function.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Vigor Gas Purification Technologies (Europe) GmbH - Marktheidenfeld, Germany
Dräger AG Invests in Digital Health Startup GWA Hygiene - Digital hygiene solutions for hospitals
Scil Proteins Signs Research Collaboration with the Martin Luther University Halle-Wittenberg for Gastrointestinal Tumors
On-the-spot genome analysis
Chemical trick activates antibiotic directly at the pathogen - Click-to-release technique avoids the severely nephrotoxic effect of colistin
Study reveals decisive role of PDK1 enzyme in acute myeloid leukaemia - PDK1: a determining factor in different metabolic states
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies - Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech
TA Instruments - Eschborn, Germany
Parkinson’s disease: When the Cellular Waste Collector Doesn’t Show Up - Mechanism identified that promotes the breakdown of harmful protein deposits. If it malfunctions, it can lead to Parkinson’s disease
Key step toward custom-made nanoscale chemical factories
United_States_Department_of_Health_and_Human_Services